SHPG - Shire plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
178.15
+1.84 (+1.04%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close176.31
Open176.43
Bid0.00 x 2200
Ask0.00 x 800
Day's Range176.33 - 178.32
52 Week Range123.73 - 178.32
Volume1,054,024
Avg. Volume774,584
Market Cap52.803B
Beta1.30
PE Ratio (TTM)11.26
EPS (TTM)15.82
Earnings DateN/A
Forward Dividend & Yield1.06 (0.60%)
Ex-Dividend Date2018-09-06
1y Target Est201.82
Trade prices are not sourced from all markets
  • GlobeNewswire23 hours ago

    Shire plc: Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • Company News For Sep 17, 2018
    Zacks2 days ago

    Company News For Sep 17, 2018

    Companies In The News are: ADBE,LB,NI,SHPG

  • GlobeNewswire2 days ago

    Shire plc: Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • Takeda gets China's approval for $62 billion Shire purchase
    Reuters5 days ago

    Takeda gets China's approval for $62 billion Shire purchase

    The acquisition, which will be the largest overseas purchase by a Japanese company, has already received unconditional clearance from U.S. and Brazilian regulators and awaits approval from Japan and the European Union. Takeda expects the deal to close in the first half of 2019. Takeda's stock is down 15 percent since the company first said it was considering a bid for Shire, with investors concerned about the heavy debt burden the deal will impose on the drugmaker.

  • Takeda gets China's approval for $62 billion Shire purchase
    Reuters5 days ago

    Takeda gets China's approval for $62 billion Shire purchase

    The acquisition, which will be the largest overseas purchase by a Japanese company, has already received unconditional clearance from U.S. and Brazilian regulators and awaits approval from Japan and the European Union. Takeda expects the deal to close in the first half of 2019. Takeda's stock is down 15 percent since the company first said it was considering a bid for Shire, with investors concerned about the heavy debt burden the deal will impose on the drugmaker.

  • GlobeNewswire5 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • Takeda weighs sale of Shire's eye care business to cut debt: Bloomberg
    Reuters6 days ago

    Takeda weighs sale of Shire's eye care business to cut debt: Bloomberg

    Japan's Takeda Pharmaceutical is considering selling Shire Plc's eye care business once it closes its $62 billion purchase of the London-listed drugmaker, as it looks to cut the debt raised to fund the ...

  • Takeda weighs sale of Shire's eye care business to cut debt - Bloomberg
    Reuters6 days ago

    Takeda weighs sale of Shire's eye care business to cut debt - Bloomberg

    (Reuters) - Japan's Takeda Pharmaceutical is considering selling Shire Plc's (SHP.L) eye care business once it closes its $62 billion (47 billion pounds) purchase of the London-listed drugmaker, as it ...

  • GlobeNewswire6 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • Takeda Is Said to Weigh Sale of Shire Eye Drug to Cut Debt
    Bloomberg6 days ago

    Takeda Is Said to Weigh Sale of Shire Eye Drug to Cut Debt

    Takeda Pharmaceutical Co. is weighing the sale of a Shire Plc eye care business once its $62 billion purchase of the U.K.-listed biotech firm is completed, as it seeks ways to cut the debt raised to fund the deal, people familiar with the matter said. The Xiidra drug, used to treat dry eye disease, is among potential divestments being assessed by Takeda, according to the people, who asked not to be identified because the matter is private. Takeda has also been discussing with banks about a possible sale of Shire’s Natpara medicine, used to control low blood calcium levels related to decreased parathyroid hormone, the people said.

  • Takeda to pack up Illinois HQ, nearly 1,000 workers to be affected
    Reuters7 days ago

    Takeda to pack up Illinois HQ, nearly 1,000 workers to be affected

    The Deerfield site employs just under 1,000 people — about a fifth of its U.S. employees — and a number of them will be provided with job offers and/or relocation opportunities, a Takeda spokeswoman told Reuters on Wednesday. "This move, while difficult, will allow closer collaboration across Takeda to best position our future pipeline for success. In May, Takeda agreed to buy London-listed Shire for 45.3 billion pounds ($62 billion), a deal that will make the firm closer to becoming a top 10 global drugmaker.

  • GlobeNewswire7 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • GlobeNewswire7 days ago

    Shire Granted EU Marketing Authorization for Veyvondi® for Adults With Von Willebrand Disease

    September 12, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) the global biotech leader in rare diseases, announced today that the European Commission (EC) has granted Marketing Authorization for VEYVONDI [vonicog alfa, recombinant von Willebrand factor] (rVWF), for the treatment of bleeding events and treatment/prevention of surgical bleeding in adults (age 18 and older) with von Willebrand disease (VWD) when desmopressin (DDAVP) treatment alone is ineffective or not indicated.

  • Shire backs out of deal to lease iconic Genzyme building in Cambridge
    American City Business Journals7 days ago

    Shire backs out of deal to lease iconic Genzyme building in Cambridge

    The surprising move frees up a prime piece of real estate in the red-hot biotech market of Kendall Square. “This space will be very, very competitive," said the director of research for Colliers International in Boston.

  • GlobeNewswire8 days ago

    Shire plc: Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • PR Newswire8 days ago

    Shire Announces The Pricing Terms And Increase In The Maximum Tender Amount Of The Previously Announced Cash Tender Offers For Certain Outstanding Notes

    The Company has also announced that the Offerors have increased the aggregate principal amount of Notes that may be purchased from $2,250,000,000 to $2,325,254,000 (as amended, the "Aggregate Maximum Purchase Amount"). The terms and conditions of the Tender Offer are described in the Offer to Purchase (the "Offer to Purchase") and related Letter of Transmittal, each dated August 24, 2018, and remain unchanged except as amended hereby.

  • GlobeNewswire8 days ago

    SHIRE ANNOUNCES THE PRICING TERMS AND INCREASE IN THE MAXIMUM TENDER AMOUNT OF THE PREVIOUSLY ANNOUNCED CASH TENDER OFFERS FOR CERTAIN OUTSTANDING NOTES

    The Company has also announced that the Offerors have increased the aggregate principal amount of Notes that may be purchased from $2,250,000,000 to $2,325,254,000 (as amended, the “Aggregate Maximum Purchase Amount”). The terms and conditions of the Tender Offer are described in the Offer to Purchase (the “Offer to Purchase”) and related Letter of Transmittal, each dated August 24, 2018, and remain unchanged except as amended hereby. The Total Consideration for each series of Notes is based on the applicable reference yield plus a fixed spread over the yield to maturity of the applicable U.S. Treasury Security specified in the table below, and is payable to holders of the Notes who validly tendered and did not validly withdraw their Notes on or before 5:00 p.m., New York City time, on September 7, 2018 (the “Early Tender Date”) and whose Notes are accepted for purchase by the Offerors.

  • Shire's ADHD Portfolio Remains Strong Amid Competition
    Zacks8 days ago

    Shire's ADHD Portfolio Remains Strong Amid Competition

    Shire (SHPG) has a strong hold in the attention deficit hyperactivity disorder (ADHD) market despite facing competition.

  • PR Newswire9 days ago

    Shire Announces Early Results Of The Previously Announced Cash Tender Offers For Certain Outstanding Notes

    DUBLIN , Sept. 10, 2018 /PRNewswire/ -- Shire plc (LSE: SHP and NASDAQ: SHPG) ("Shire"), Baxalta Incorporated, a Delaware corporation and wholly-owned subsidiary of Shire ("Baxalta"), ...

  • GlobeNewswire9 days ago

    SHIRE ANNOUNCES EARLY RESULTS OF THE PREVIOUSLY ANNOUNCED CASH TENDER OFFERS FOR CERTAIN OUTSTANDING NOTES

    As of 5:00 p.m. New York City time, on September 7, 2018 (the “Early Tender Date”), the principal amounts of the Notes listed in the table below had been validly tendered and not validly withdrawn. Pursuant to the terms of the Tender Offers, the amount of Notes that will be accepted for purchase is subject to the Aggregate Maximum Purchase Amount.

  • GlobeNewswire9 days ago

    Shire plc: Elections for the interim dividend in respect of the six months to June 30, 2018

    Elections for the interim dividend in respect of the six months to June 30, 2018. September 10, 2018- Shire plc announced on July 31, 2018, an interim dividend of 5.60 US cents per Ordinary Share payable ...

  • GlobeNewswire13 days ago

    Shire Acquires sanaplasma AG Boosting Plasma Collection Network for Immunology Franchise

    Shire Acquires sanaplasma AG Boosting Plasma Collection Network for Immunology Franchise. The acquisition of sanaplasma AG will extend long-term plasma supply in support of Shire’ s growing Immunology ...

  • GlobeNewswire13 days ago

    Shire plc: Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • GlobeNewswire15 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • GlobeNewswire16 days ago

    Shire plc: Total voting rights

    September 3, 2018- Shire plc, in accordance with 5.6. 1 R of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, notifies the market of the following:. As at August 31, 2018, ...